BACKGROUND The emergence of secondary drug resistance when treating epidermal growth factor receptor(EGFR)mutated non-small cell lung cancer(NSCLC)using EGFRtyrosine kinase inhibitors(EGFR-TKIs),seriously affects the ...BACKGROUND The emergence of secondary drug resistance when treating epidermal growth factor receptor(EGFR)mutated non-small cell lung cancer(NSCLC)using EGFRtyrosine kinase inhibitors(EGFR-TKIs),seriously affects the therapeutic efficacy and survival of patients.Here,we report a case of advanced NSCLC focusing on the application of multiple biopsy modalities to reveal the development of multiple resistance mechanisms during targeted therapies.CASE SUMMARY A 54-year-old male patient presented with EGFR 19Del-mutated advanced lung adenocarcinoma,and exhibited the development of a T790M mutation during initial TKI treatment.Following 3 mo of Osimertinib treatment,a mixed response was observed.Tissue biopsy of the progressive lesion showed transformation to small cell lung cancer(SCLC)harboring RB1 and TP53 mutations,with loss of the original T790M mutation.A standard chemotherapy regimen with Anlotinib for SCLC was administered.Repeat biopsy revealed adenocarcinoma combined with SCLC after tumor progression.The patient’s overall survival was 24 mo.CONCLUSION Multiple biopsy modalities can reveal the development of multiple resistance mechanisms which help with treatment decision-making.Comprehensive treatment regimens according to the drug resistance mechanism significantly improved the prognosis of such patients.展开更多
Lung cancer is a leading cause of cancer deaths worldwide,consisting of two major histological subtypes:small-cell lung cancer(SCLC)and non-small-cell lung cancer(NSCLC).In some cases,NSCLC patients may undergo a hist...Lung cancer is a leading cause of cancer deaths worldwide,consisting of two major histological subtypes:small-cell lung cancer(SCLC)and non-small-cell lung cancer(NSCLC).In some cases,NSCLC patients may undergo a histological transformation to SCLC during clinical treatments,which is associated with resistance to targeted therapy,immunotherapy,or chemotherapy.The review provides a comprehensive analysis of SCLC transfor-mation from NSCLC,including biological mechanism,clinical relevance,and potential treatment options after transformation,which may give a better understanding of SCLC transformation and provide support for further research to define better therapy options.展开更多
文摘BACKGROUND The emergence of secondary drug resistance when treating epidermal growth factor receptor(EGFR)mutated non-small cell lung cancer(NSCLC)using EGFRtyrosine kinase inhibitors(EGFR-TKIs),seriously affects the therapeutic efficacy and survival of patients.Here,we report a case of advanced NSCLC focusing on the application of multiple biopsy modalities to reveal the development of multiple resistance mechanisms during targeted therapies.CASE SUMMARY A 54-year-old male patient presented with EGFR 19Del-mutated advanced lung adenocarcinoma,and exhibited the development of a T790M mutation during initial TKI treatment.Following 3 mo of Osimertinib treatment,a mixed response was observed.Tissue biopsy of the progressive lesion showed transformation to small cell lung cancer(SCLC)harboring RB1 and TP53 mutations,with loss of the original T790M mutation.A standard chemotherapy regimen with Anlotinib for SCLC was administered.Repeat biopsy revealed adenocarcinoma combined with SCLC after tumor progression.The patient’s overall survival was 24 mo.CONCLUSION Multiple biopsy modalities can reveal the development of multiple resistance mechanisms which help with treatment decision-making.Comprehensive treatment regimens according to the drug resistance mechanism significantly improved the prognosis of such patients.
基金supported by grants from the National Natural Sci-ence Foundation of China(Nos.82272722,82200019,82102805,and 81773218)the Natural Sciences Foundations of Hunan Province(Nos.2020JJ4122,2021JJ40890,and 2021JJ30904).
文摘Lung cancer is a leading cause of cancer deaths worldwide,consisting of two major histological subtypes:small-cell lung cancer(SCLC)and non-small-cell lung cancer(NSCLC).In some cases,NSCLC patients may undergo a histological transformation to SCLC during clinical treatments,which is associated with resistance to targeted therapy,immunotherapy,or chemotherapy.The review provides a comprehensive analysis of SCLC transfor-mation from NSCLC,including biological mechanism,clinical relevance,and potential treatment options after transformation,which may give a better understanding of SCLC transformation and provide support for further research to define better therapy options.